We are live on ! Find out more
VMI

VHCP Management III Portfolio holdings

AUM $504M
1-Year Est. Return 683.12%
This Fund
S&P 500
This Quarter Est. Return
+61.32%
1 Year Est. Return
+683.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$172M
AUM Growth
+$34M
Cap. Flow
+$2.64M
Cap. Flow %
1.54%
Top 10 Hldgs %
92.24%
Holding
17
New
2
Increased
2
Reduced
4
Closed
1

Top Buys

Rank Stock Value
1
AXSM icon
Axsome Therapeutics
AXSM
+$9.92M
2
LJPC
La Jolla Pharmaceutical Company
LJPC
+$6.54M
3
PTGX icon
Protagonist Therapeutics
PTGX
+$3.41M
4
BLPH
Bellerophon Therapeutics, Inc.
BLPH
+$105K

Top Sells

Rank Stock Value
1
KALV
KalVista Pharmaceuticals
KALV
+$6.81M
2
DBVT
DBV Technologies
DBVT
+$4.09M
3
ORTX
Orchard Therapeutics plc American Depositary Shares
ORTX
+$3.46M
4
KDMN
Kadmon Holdings, Inc.
KDMN
+$2.52M
5
KA
Kineta, Inc. Common Stock
KA
+$439K

Sector Composition

Rank Sector Weight
1 Healthcare 96.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KALV
1
DELISTED
KalVista Pharmaceuticals
KALV
$27.8M 16.19%
970,630
-314,301
-24% -$6.81M
TCDA
2
DELISTED
Tricida, Inc. Common Stock
TCDA
$25.1M 14.65%
650,585
– –
BCRX icon
3
BioCryst Pharmaceuticals
BCRX
$2.28B
$24.9M 14.53%
3,061,091
– –
AXSM icon
4
Axsome Therapeutics
AXSM
$11.2B
$15.2M 8.86%
+1,068,044
New +$9.92M
OBSV
5
DELISTED
ObsEva SA Ordinary Shares
OBSV
$14.8M 8.65%
1,159,789
– –
ORTX
6
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$14.5M 8.45%
81,103
-23,049
-22% -$3.46M
RARX
7
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$13.3M 7.77%
594,713
– –
PTGX icon
8
Protagonist Therapeutics
PTGX
$8.79B
$10.2M 5.93%
809,323
+386,147
+91% +$3.41M
LJPC
9
DELISTED
La Jolla Pharmaceutical Company
LJPC
$6.45M 3.76%
+1,003,600
New +$6.54M
KNSA icon
10
Kiniksa Pharmaceuticals
KNSA
$5.8B
$5.92M 3.45%
327,777
– –
MRNS
11
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$5.26M 3.07%
314,741
– –
KDMN
12
DELISTED
Kadmon Holdings, Inc.
KDMN
$3.66M 2.14%
1,387,874
-1,000,698
-42% -$2.52M
BLPH
13
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
$1.58M 0.92%
161,148
+9,523
+6% +$105K
MTVA
14
MetaVia Inc
MTVA
$7.33M
$1M 0.58%
13
– –
KA
15
DELISTED
Kineta, Inc. Common Stock
KA
$911K 0.53%
5,164
-898
-15% -$439K
CNST
16
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$903K 0.53%
66,667
– –
DBVT
17
DBV Technologies
DBVT
$799M
– –
-63,680
Closed -$4.09M

Similar funds

BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
LB
Landmark Bank Columbia, Missouri $444M AUM 30.12% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
VOAM
Vertex One Asset Management Vancouver, British Columbia, Canada $434M AUM 37.82% 1-Year Est. Return
PC
Passport Capital San Francisco, California $394M AUM 50.67% 1-Year Est. Return
FFSOTS
Fiduciary Financial Services of The Southwest Dallas, Texas $382M AUM 25.98% 1-Year Est. Return
SC
Southside Capital Miami Beach, Florida $382M AUM 30.29% 1-Year Est. Return

VHCP Management III's Q1 2019 Portfolio in Review

As of Q1 2019, VHCP Management III held 17 positions worth $172M, up 25% from $138M the previous quarter. Its ten largest holdings account for 92% of the portfolio.

VHCP Management III's Q1 2019 filing shows 2 new, 2 increased, 4 reduced and 1 closed positions. Its largest new stake was Axsome Therapeutics: 1,068,044 shares worth $15.2M. The largest sale was KalVista Pharmaceuticals, an estimated $6.81M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier.

  • VHCP Management III's largest Q1 2019 buy was Axsome Therapeutics: 1,068,044 shares worth $15.2M.
  • VHCP Management III added most to Protagonist Therapeutics in Q1 2019, an estimated $3.41M increase.
  • VHCP Management III's biggest Q1 2019 reduction was KalVista Pharmaceuticals, cutting an estimated $6.81M.
  • VHCP Management III fully exited DBV Technologies in Q1 2019, selling an estimated $4.09M.
  • VHCP Management III's ten largest holdings make up 92% of its $172M portfolio in Q1 2019.
  • VHCP Management III opened 2 new positions and closed 1 in Q1 2019.
  • VHCP Management III's portfolio value rose 25% quarter-over-quarter to $172M.

Based on VHCP Management III's 13F filing for Q1 2019, filed 14 May 2019.